Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL

Abstract: De novo resistance and rapid recurrence often characterize responses of B-cell malignancies to ibrutinib (IBR), indicating a need to develop drug combinations that block compensatory survival signaling and give deeper, more durable responses. To identify such combinations, we previously pe...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Kallesh D. Jayappa, Craig A. Portell, Vicki L. Gordon, Brian J. Capaldo, Stefan Bekiranov, Mark J. Axelrod, L. Kyle Brett, Julia D. Wulfkuhle, Rosa I. Gallagher, Emanuel F. Petricoin, Timothy P. Bender, Michael E. Williams, Michael J. Weber
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Elsevier 2017-06-01
Serie:	Blood Advances
Accesso online:	http://www.sciencedirect.com/science/article/pii/S2473952920302056
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!